Las Vegas, NV -- (SBWIRE) -- 01/10/2014 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Nordic American Tanker Ltd(NYSE:NAT), ReneSola Ltd. (ADR)(NYSE:SOL), Orexigen Therapeutics, Inc.(NASDAQ:OREX), Hovnanian Enterprises, Inc.(NYSE:HOV)
Nordic American Tanker Ltd(NYSE:NAT) was a volume gainer of 3.70 million shares and the average volume of the stock remained 1.70 million shares. The stock opened the session at $9.89 and finished at the end of the day at $9.58 and the stock plunged -6.90% .The market capitalizations of the stock remained 632.76 million. Nordic American Tankers Limited, a tanker company, engages in acquiring and chartering double-hull tankers. Its fleet consists of 20 double-hull Suezmax tankers. The company was founded in 1995 and is headquartered in Hamilton, Bermuda.
Has NAT Found The Bottom And Ready To Gain Momentum? Find Out Here
In the preceding trading session, ReneSola Ltd. (ADR)(NYSE:SOL) exchanged 3.62 million shares and the average volume remained 4.15 million shares. The stock closed the session at $4.08 with the drop of -2.16%. ReneSola Ltd operates as a brand and technology provider of solar photovoltaic (PV) products. The company, through its subsidiaries, engages in the research and development, and manufacture of virgin polysilicon, monocrystalline and multicrystalline silicon wafers, and PV cells and modules. ReneSola Ltd was founded in 2005 and is based in Jiashan, the People?s Republic of China.
Why Should Investors Buy SOL After the Recent Fall? Just Go Here and Find Out
Orexigen Therapeutics, Inc.(NASDAQ:OREX) enhanced 4.67% and its closing price was $6.27. The volume of the stock was 3.51 million shares and the average volume remained 3.35 million shares. The market capitalization of the stock remained 635.61 million. The beta of the stock remained 2.11. Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include Contrave, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic, which has completed Phase II clinical trials.
Why Should Investors Buy OREX After The Recent Gain? Just Go Here and Find Out
Hovnanian Enterprises, Inc.(NYSE:HOV) exchanged 3.48 million shares in the previous trading session, and its average trading remained 4.63 million shares. HOV it closed the trading at $6.20. The market capitalization of the stock remained 863.05 million. Hovnanian Enterprises, Inc. designs, constructs, markets, and sells residential homes in the United States. It constructs single-family detached homes, attached townhomes and condominiums, urban infill, and active adult homes. The company was founded in 1959 and is headquartered in Red Bank, New Jersey.
How Should Investors Trade HOV Now? Don’t Miss out a Special Trend Analysis
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)